Prolonged mpox infection and fatal outcome in an HIV patient treated with tecovirimat.
Berta Pino-Calm, Ariadna Fuentes-Martin, Diego García-Martínez De Artola et al.
✦ AI-curated · Sources linked
Case in brief
A 59-day mpox infection was observed in a highly immunocompromised HIV-positive patient. The patient exhibited progressive viral diversification across lesions from various anatomical sites, culminating in a fatal outcome. Notably, a mutation linked to tecovirimat resistance emerged during the infection, underscoring the challenges in managing mpox in severely immunocompromised individuals.
What made this case unusual
The case is notable for the emergence of a mutation associated with tecovirimat resistance during a prolonged mpox infection.
Diagnostic / clinical pearl
Clinicians should be aware of the potential for viral diversification and resistance mutations in severely immunocompromised patients undergoing treatment for mpox.
Why it matters
This case emphasizes the necessity for alternative therapeutic strategies for managing mpox in patients with significant immunocompromise.